The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.25
Bid: 19.00
Ask: 19.50
Change: -0.25 (-1.28%)
Spread: 0.50 (2.632%)
Open: 19.50
High: 19.50
Low: 18.50
Prev. Close: 19.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Re Synature Ltd

15 Nov 2005 07:03

Angle PLC15 November 2005 For immediate release 15 November 2005 ANGLE plc ("ANGLE") SENIOR APPOINTMENTS AND VENTURE UPDATE ANGLE plc the venture management and consulting company specialising in thecommercialisation of technology and the development of technology-based industryis pleased to announce two senior appointments at its venture company, SynatureLtd. Founded earlier this year, Synature Ltd (formerly known as Customiser Group Ltd)provides psychological profiling tools that engage the consumer, deliveringinsight into individual attitudes and consumer preferences complementingtraditional demographic models. Based in Guildford Surrey, Synature Ltd is oneof ANGLE's eight venture companies. Dr. John Woods joins Synature Ltd as Chief Executive Officer. Previously founderand Chief Executive of Site Intelligence Ltd, one of the UK's most successfulweb analytics companies, John has worked with clients such as Argos, Expedia,SAP and Lloyds TSB. Dr. Woods has 15 years' experience in commercialisation and marketing ofadvanced software technologies. He holds a doctorate from Jesus College, Oxfordand an MBA. Commenting on his appointment, Dr. Woods said "I am delighted to be joining the Synature team at this exciting stage in thecompany's development. Marketing departments have a growing appetite forenhanced profiling and targeting of online and offline customers. Synature'sunique intellectual property offers a compelling way to meet that need.Moreover, ANGLE provides Synature with a supportive environment in which thatcompelling intellectual property can be rapidly and successfully commercialised." Professor William J. Fitzgerald joins Synature Ltd as a consultant technicaladvisor. He is Professor of Applied Statistics and Signal Processing and Headof the Signal Processing and Communications Laboratory at the University ofCambridge. He consults for a number of successful high technology companies inboth the UK and USA. Professor Fitzgerald commented: "Synature's consumer profiling techniques demonstrate the real world businessbenefits that can be obtained from state-of-the-art data analysis and patternrecognition. I am excited to be part of the team and to be ensuring thatSynature's clients receive maximum insight and maximum value from theapplication of our technologies." Stephen Bence, Director of New Ventures at ANGLE, added: "These two key appointments complement Synature's existing founding team andprovide the company with additional commercial and technical expertise. We areexcited about the opportunity that Synature's unique intellectual propertyrepresents." For further information ANGLE plc 01483 295830Andrew Newland, Chief ExecutiveStephen Bence, Director of New Ventures Synature Ltd 08701 909550John Woods, Chief Executive Buchanan Communications 020 7466 5000Richard Darby, James Strong Notes to Editors Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE is listed on AIM (AGL.L)and operates from offices in the UK, the US and the Middle East. Further information can be found on www.ANGLEplc.com Synature Ltd is an ANGLE Technology group company formed to commercialiseintellectual property acquired in 2005 from Customiser Ltd. Synature'sintellectual property provides unique ways to profile consumers in terms oftheir underlying preferences. The resulting profiles allow fine-grainedconsumer segmentation that complements traditional demographics. Synature'stechniques can be applied both online and offline. Further information can be found on www.synature.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery
5th Dec 20237:00 amRNSANGLE launches Portrait+ CTC kit at SABCS
9th Nov 20237:00 amRNSLaunch of PD-L1 test to support cancer studies
9th Nov 20237:00 amRNSTrading and business update
25th Oct 20237:00 amRNSSupporting characterisation of CTCs in HNSCC
3rd Oct 20237:00 amRNSParsortix outperforms standard for DTC harvest
29th Sep 20237:00 amRNSParsortix system showcased at ACTC conference
7th Sep 20237:00 amRNSInterim Results for the period ended 30 June 2023
4th Sep 20237:00 amRNSANGLE launch of Portrait Flex assay
15th Aug 20237:00 amRNSANGLE notice of interim results
28th Jun 20234:54 pmRNSResult of 2023 Annual General Meeting
27th Jun 202312:24 pmRNSStandard form for notification of major holdings
5th Jun 20237:00 amRNSANGLE announces senior management appointments
25th May 20237:00 amRNSPharma services contract with Artios Pharma
22nd May 20237:00 amRNSBoard change - appointment of new Chairman
21st Apr 202312:04 pmRNSANGLE presentation via Investor Meet Company
21st Apr 20237:00 amRNSResults for the year ended 31 December 2022
19th Apr 20237:00 amRNSANGLE announces partnership with BioView
17th Apr 20237:00 amRNSANGLE Parsortix poster presented at AACR 2023
13th Apr 20237:00 amRNSPharma Services Contract with Crescendo Biologics
3rd Apr 20237:00 amRNSNotice of Preliminary Results and Webcast
10th Mar 20237:00 amRNSIssue of LTIP Options and Share Options
9th Mar 20233:03 pmRNSHolding(s) in Company
9th Feb 20232:44 pmRNSDirector/PDMR shareholding
19th Jan 20237:00 amRNSAppointment of Non-Executive Director
11th Jan 20235:20 pmRNSHolding(s) in Company
10th Jan 20236:20 pmRNSHolding(s) in Company
6th Jan 202311:05 amRNSSecond Price Monitoring Extn
6th Jan 202311:00 amRNSPrice Monitoring Extension
5th Jan 20239:05 amRNSSecond Price Monitoring Extn
5th Jan 20239:00 amRNSPrice Monitoring Extension
5th Jan 20237:01 amRNSAppointment of Non-Executive Director
5th Jan 20237:00 amRNSBusiness Update
12th Dec 20227:00 amRNSTwo Parsortix posters presented at SABCS
2nd Dec 20225:30 pmRNSIssue of Equity
2nd Nov 20227:00 amRNSMultiple downstream analysis techniques for CTCs
1st Nov 20224:41 pmRNSSecond Price Monitoring Extn
1st Nov 20224:35 pmRNSPrice Monitoring Extension
24th Oct 20227:00 amRNSParsortix poster presented at ISLB meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.